UCB S.A.'s just-completed acquisition of Zogenix, Inc. already looked like a shrewd bit of business and the up-to-$1.9bn purchase is increasingly looking like a snip now that the epilepsy drug Fintepla has secured another approval in the US, this time for Lennox-Gastaut syndrome (LGS).
UCB's Zogenix Bet Pays Out Quickly With Fresh Fintepla Approval
Second Indication For Rare Epilepsy Potential Blockbuster
Gaining approval for Fintepla in Lennox-Gastaut syndrome, on top of an earlier green light in Dravet, puts the Belgian group in a strong position to compete with Jazz’s Epidiolex.
